Table 1 Clinical characteristics of the study population
Characteristics | Prostate cancer, n = 50 | Benign prostatic hyperplasia, n = 22 |
|---|---|---|
Age (years) | ||
Mean ± SD | 66 ± 7 | 61 ± 8 |
Median (range) | 65 (54–85) | 60 (44–75) |
Missing | 1 | 4 |
Serum PSA (ng/ml) | ||
0–4.0 | 3 (6%) | 9 (41%) |
4.1–20.0 | 31 (62%) | 13 (59%) |
> 20.0 | 15 (30%) | 0 (0%) |
Missing | 1 (2%) | 0 (0%) |
Gleason score | ||
4–6 | 26 (52%) | – |
8–9 | 24 (48%) | – |
Metastasis status | ||
M0 | 39 (78%) | – |
M1 | 3 (6%) | – |
Missing | 8 (16%) | – |
Cancer grade | ||
G1 | 0 (0%) | – |
G2 | 11 (22%) | – |
G3 | 12 (24%) | – |
Missing | 27 (54%) | – |
Prostatitis | ||
– | 40 (80%) | 11 (50%) |
+ | 8 (16%) | 11 (50%) |
Missing | 2 (4%) | 0 (0%) |